Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q3 base-business sales rose 16%, Gilead raised its full-year revenue outlook, and cash generation remained strong. Shares gained about 9.5% through November 16; a move above $170â$174.50 resistance would strengthen the setup.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Annual Cashflow ⢠Major Earnings Shock ⢠Rising Leverage Risk GILD's strong 2025 profitability and cash flow are overshadowed by a severe 2026 earnings shock, falling liquidity, and sharply higher leverage, warranting caution.
Price Behavior
Key Price Behavior Insights: ⢠Positive momentum ⢠Resistance test ⢠Support holding Support Level: $145.50â$145.80; stronger $142.60â$144.00 Resistance Level: $150.15â$150.90 GILD gained 5.2% over the last month and remains constructive above support, but a sustained break above $150.90 is needed to confirm further upside.
Sentiment & News
Key News Insights: ⢠Strong Buy upgrade ⢠FDA approval momentum ⢠Institutional accumulation Gilead's bullish analyst outlook, FDA approvals, pipeline diversification, and institutional buying support a positive near-term investment case.
AI Summary
Gilead is shifting from a mature HIV-dividend story to an execution-driven growth transition led by long-acting HIV prevention and oncology, but investors should demand proof that new launches can scale profitably without further weakening its leveraged, impairment-sensitive balance sheet.
Description
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes prescription medicines for unmet medical needs in the United States, Europe and other markets. Its marketed portfolio spans antiviral therapies for HIV, COVIDâ19 and liver disease, oncology and cellâtherapy products, and treatments for cardiopulmonary and serious fungal conditions. The company maintains collaborations with multiple biotech and pharmaceutical partners and is headquartered in Foster City, California; it was incorporated in 1987.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 17 | Nov 24 | GILD | Gilead Sciences, Inc. | Q3 base-business sales rose 16%, Gilead raised its full-year revenue outlook, and cash generation remained strong. Shares gained about 9.5% through November 16; a move above $170â$174.50 resistance would strengthen the setup. | Active | -2.3% |